Stay updated with breaking news from Actionable Drivers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The LEADER trial will use the firm's FDA-approved FoundationOne CDx and FoundationOne Liquid CDx comprehensive genomic profiling tests.
/PRNewswire/ -- The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the initiation of trial sites...
Pivotal data on glofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading